REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS
|3 Months Ended|
Mar. 31, 2022
|REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS|
|REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS||
NOTE 18. REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS
Disaggregation of Net Revenues
The Company’s net product revenues are summarized as follows:
The above table includes the authorized generic product within the line items for Targadox®, Ximino® and Exelderm®.
For the three-month periods ended March 31, 2022 and 2021, there were no customers that accounted for more than 10% of the Company’s total gross product revenue.
At March 31, 2022, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 15% and 10%. At December 31, 2021, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 16% and 13%.
Other revenue for the three-month period ended March 31, 2022 reflects a net $2.5 million milestone payment from the Company's exclusive out-licensing partner in Japan, Maruho Co., Ltd (“Maruho”). In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the net payment. The net payment reflects a milestone payment of $10.0 million to the Company from Maruho, offset by a $7.5 million payment to Dermira, Inc., pursuant to the terms of the Asset Purchase Agreement between the Company and Dermira.
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef